On December 3, 03692.HK 2017, Gelonghui Announced that the innovative drug "emitiofovir tablets" (trade name: Hengmu ®) independently developed by Jiangsu Haosen Pharmaceutical Group Co., Ltd., a subsidiary of the Company, has been included in the new version of the National Medical Insurance Catalogue ("National Medical Insurance Catalogue") issued by the National Medical Security Bureau of China.
The product was approved by the State Drug Administration of the People's Republic of China in June 2021 as an anti-infective drug suitable for the treatment of chronic hepatitis B in adult patients.
The announcement said that the inclusion of the product in the national medical insurance directory will help the group further improve the affordability and accessibility of the product among patients.
This article originated from Grand Gateway
![Iron-blooded Northern Dynasty 69: One Yuzhou two thorn history, why Northern Wei and Southern Qi are desperate to fight[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)